Industry News

Novasep selects Thierry van Nieuwenhove as new president of the synthesis business unit.

Lonza signs an agreement with Index Ventures for the development and manufacture of biologics for portfolio companies.

USP opens expanded Shanghai facility to enhance quality standards for medicines and food ingredients.

CCBR–SYNARC and BioClinica merge to create a provider of specialized outsourced clinical services.

A packaging defect has led to Merck voluntarily recalling all lots of Liptruzet tablets in the United States.

CytomX Therapeutics and ImmunoGen announce collaboration to develop probody-drug conjugate therapies for the treatment of cancer.

Eurofins acquires DDS business of Merck KGaA in order to expand discovery solutions and bioanalytical services.

LSNE completes an FDA inspection of its Manchester manufacturing facility.Lyophilization Services of New England (LSNE),

Genzyme plans to appeal FDA?s decision that the multiple-sclerosis treatment is not ready for approval.

Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI's LifeSciences business unit for $185 million.

Merck and GlaxoSmithKline begin clinical trial of pazopanib for the treatment of advanced renal-cell carcinoma.

Bind Therapeutics amends its development and commercialization collaboration agreement with Amgen.

CMC Biologics and OnoSynergy form an agreement from cell-line development.

Pfizer appoints management changes to take effect in 2014.

Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.

Siemens enters agreement with Pfizer to commercialize diagnostic tests for therapeutic products across Pfizer's pipeline.

ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.

Almost 400 new medicines for infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections.

Johnson&Johnson will open a network of partnering offices across the UK.

BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.

Octapharma and Pfizer form an agreement for the future marketing and commercialization of human prothrombin complex concentrate.

GSK forms the Oncology Clinical and Translational Consortium, a scientific research network comprised of six international cancer centers.

Bristol-Myers Squibb has elected Thomas Lynch, Jr., MD to its board of directors.

LSNE appoints Shawn Cain as COO, a new position within the company.

TxCell has received manufacturing accreditation status of its cell-therapy production site in Besancon, France, from the French National Agency for Drug Safety (ANSM).

SGS Life Science Services announced that its bioanalytical laboratory in Poitiers, France has received GMP certification, following approval from ANSM.

Almac releases an enhanced third-party logistics customer billing application.

GSK and Amicus Therapeutics revise Fabry agreement entered into in July 2012.